This includes the use the use of the TKI cabozantinib, with activity against VEGFR2, and Nivolumab (anti-PD-1) specifically in patients with non-clear cell RCC including SDH-RCC (NCT03635892). The gene discussed is SDHB; the disease is renal cell carcinoma.